Tag
This study demonstrates that nucleos(t)ide analogue therapy significantly reduces cirrhosis and hepatocellular carcinoma risk in specific HBeAg-positive chronic HBV infection phases beyond current EASL 2025 treatment indications.
Pegylated interferon-alpha after nucleos(t)ide analog withdrawal induces coordinated expansion of regulatory B cells and contraction of HBV-specific T cells, impacting viral control and hepatic inflammation in HBeAg-negative chronic hepatit
The RADICAL consortium’s large-scale study reveals a high long-term transition rate from immune tolerant to immune active chronic hepatitis B, especially in patients with high-normal ALT, suggesting the need for closer monitoring and
AHB-137, an antisense oligonucleotide targeting HBV mRNA, demonstrated safety, favorable pharmacokinetics, and rapid HBsAg reduction in healthy volunteers and chronic hepatitis B patients, supporting further clinical development.
This study evaluates the long-term incidence of liver cancer in chronic hepatitis B patients who clear hepatitis B surface antigen, finding significantly reduced cancer risk in younger patients without cirrhosis.
This review synthesizes evidence on preS1 antigen and anti-preS1 IgG dynamics in chronic hepatitis B, highlighting their correlations with viral replication, liver inflammation, and functional cure, and elucidates the neutralising potential
In NA-treated cirrhotic chronic hepatitis B with complete viral suppression, HBsAg seroclearance was linked to lower HCC risk but not lower hepatic decompensation, reinforcing functional cure as a meaningful but incomplete clinical endpoint
This Phase 1 trial demonstrates that ALG-000184, a novel Class-E capsid assembly modulator, significantly reduces HBV DNA and RNA levels in patients with chronic hepatitis B, maintaining a favorable safety profile and supporting its potenti
GSK has announced positive Phase III results for Bepirovirsen, an antisense oligonucleotide that achieves functional cure in chronic hepatitis B patients. By targeting viral RNA and HBsAg, the drug offers a finite treatment path, potentiall
Phase 2 studies demonstrate that elebsiran, a small interfering RNA, combined with PEG-IFNα, enhances sustained HBsAg loss rates in chronic HBV infection, offering a promising approach toward functional cure.
The B-Together phase IIb study demonstrates that sequential therapy with bepirovirsen followed by pegylated interferon-α-2a reduces post-treatment relapse in chronic hepatitis B patients on stable nucleos(t)ide analogue therapy, with enhanc
